INGEFITINIB FILM COATED TABLET 250MG

TABLET, FILM COATED

**DOSAGE AND ADMINISTRATION** INGEFITINIB treatment should only be initiated by a medical specialist experienced in the treatment of patients with advanced NSCLC. The recommended dose of INGEFITINIB is one 250 mg tablet once a day, taken with or without food. If a dose of INGEFITINIB is missed, it should be taken as soon as the patient remembers. If it is less than 12 hours to the next dose, the patient should not take the missed dose. Patients should not take a double dose (two doses at the same time) to make up for a forgotten dose. Where dosing of whole tablets is not possible, such as patients who are only able to swallow liquids, tablets may be administered as a dispersion in water. The tablet should be dropped into half a glass of drinking water (non-carbonated), without crushing, and the glass stirred until the tablet has dispersed (approximately 15 minutes) and the contents subsequently drunk immediately. The glass should be rinsed with a further half glass of water and the contents drunk. The liquid can also be administered via a nasogastric tube. INGEFITINIB is not recommended for use in children or adolescents as safety and effectiveness in these patient populations has not been studied. No dosage adjustment is required on the basis of patient age, body weight, gender, ethnicity, mild to moderate renal impairment or in patients with moderate to severe hepatic impairment due to liver metastases (see ‘PHARMACOKINETIC PROPERTIES’ section – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Dosage adjustment:** Patients with poorly tolerated diarrhoea or skin adverse drug reactions may be successfully managed by providing a brief (up to 14 days) therapy interruption followed by reinstatement of the 250 mg dose (see ‘POSSIBLE ADVERSE REACTIONS’ section – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). In the event of acute onset or worsening of pulmonary symptoms (dyspnoea, cough, fever) INGEFITINIB therapy should be interrupted and a prompt investigation of these symptoms should occur and appropriate treatment initiated. If interstitial lung disease is confirmed, INGEFITINIB should be discontinued and the patient treated appropriately. Patients who develop onset of new eye symptoms such as pain should be medically evaluated and managed appropriately, including INGEFITINIB therapy interruption and removal of an aberrant eyelash if present. After symptoms and eye changes have resolved, the decision should be made concerning reinstatement of the 250 mg daily dose.